Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Patients With Huntington's Disease (HD) Chorea in China

Inclusion Criteria: * Participants with clinically confirmed diagnosis of chorea associated with Huntington's Disease (HD) * Participants whose baseline total maximal chorea (TMC) score ≥ 8 * Participants who are deutetrabenazine-naïve before study entry or who did not receive deutetrabenazine within 30 days of study entry, and who are about to be treated with deutetrabenazine for chorea associated with HD * Participants who have provided written consent for the use of personal and medical information for study purposes Exclusion Criteria: * Participants who have an unstable or serious medical or psychiatric illness at baseline * Participants with any history of suicidality, untreated or inadequately treated depression * Participants with certain comorbidities, including hepatic impairment, congenital long QT syndrome, and clinically significant cardiac arrhythmias. * Participants who received reserpine within 20 days of deutetrabenazine treatment initiation * Participants who received monoamine oxidase inhibitors within 14 days of deutetrabenazine treatment initiation * Participants who received vesicular monoamine transporter 2 (VMAT2) inhibitors, e.g., tetrabenazine or valbenazine, within 30 days of deutetrabenazine treatment initiation * Participants unable to provide a written consent for the study. * Participants who are participating in another study that includes treatment with an investigational drug and/or intervention at the same time as enrolment in the current study